Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas Biopharma Holdings, Inc. on October 15, 2018. The filing reports the appointment of a new senior executive officer and the execution of a corresponding employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance.
Material Changes
The primary material change reported is the appointment of Dr. Theresa Matkovits as Chief Development Officer, effective October 15, 2018. Dr. Matkovits joins the company from ContraVir Pharmaceuticals, Inc., where she served as Chief Operating Officer.
Management Commentary and Compensation Details
The filing details the terms of Dr. Matkovits' employment agreement:
- Base Salary: $350,000 annually.
- Annual Bonus: Target amount of up to 35% of base salary, contingent on individual and corporate performance targets.
- Equity Grant: Options to purchase 350,000 shares of common stock under the 2013 Equity Incentive Plan.
- Severance Provisions: In the event of termination "without cause" or resignation for "good reason," Dr. Matkovits is entitled to 12 months of base salary continuation, 12 months of COBRA benefits, and acceleration of 50% of outstanding equity awards.
The filing also notes that the press release regarding this appointment is furnished as an exhibit and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the vesting schedule and exercise price for the 350,000 stock options granted to Dr. Matkovits.
- Review the specific performance targets defined in the employment agreement that determine the annual bonus.
- Confirm the impact of this appointment on the company's overall cash burn rate and equity dilution.
- Check for any subsequent filings regarding the status of Dr. Matkovits' prior employment agreements or non-compete obligations.